Description
An educational textbook covering the concepts and methods of pharmacoepidemiology (the study of the utilization and effects of drugs in large numbers of patients) Author Profiles Donna West, Ph.,Ph.D. University of Mississippi Chair of Pharmacy Administration University, MS Donna West-Strum most recently was associate professor in the Division of Pharmaceutical Evaluation and Policy at the University of Arkansas for Medical Sciences College of Pharmacy. The Germantown, Tenn., native earned her bachelor’s degree in pharmacy, master’s in pharmaceutical sciences and doctorate in pharmacy administration from UM. In 2007, she completed the Academic Leadership Fellows Program with the American Association of Colleges of Pharmacy. Her research interests focus on community pharmacy practice and using health behavior theories to study the provision, use and evaluation of pharmaceuticals and pharmacy. West-Strum has published more than 40 articles and presented more than 50 presentations at national meetings. She is active in the American Pharmacists Association and the National Community Pharmacists Association. She was the faculty liaison for the NCPA chapter at UAMS and was named NCPA Chapter Adviser of the Year in 2004. She edits the NCPA Digest, a comprehensive financial guide to community pharmacy. Yi Yang, M.D., Ph.D. University of Mississippi School of Pharmacy Assistant Professor University, MS Dr. Yi Yang is an Assistant Professor of Pharmacy Administration at the University of Mississippi. Yang received her Ph.D from both the University of Tennessee and Peking Union Medical College. She received her M.D. from China Medical University, China. 1. Introduction to Pharmacoepiedmiology 2. Principles of Epidemiology Applied to the Study of Medication Use 3. Study Designs for Pharmacoepidemiology 4. Using Secondary Data in Pharmacoepidemiology 5. Biostatistics and Pharmacoepidemiology 6. Other Methodological Issues 7. Evaluation of the Pharmaceoepidemiology Literature 8. Medication Utilization Patterns 9. Medication Safety and Pharmacovigilance 10. The FDA Perspective on Postmarket Drug Safety
